Life Science Nation (LSN) is pleased to highlight an important development from one of our long term partners. BioMetas, Title Sponsor of the RESI conferences in 2026, has announced a strategic integration with ZSHK Laboratories to build a comprehensive preclinical drug discovery and development CRO platform.
This move reflects a continued push toward greater integration across the early stages of drug development, an area where fragmentation has historically slowed progress for emerging companies.
On April 13, 2026, BioMetas Group and ZSHK Laboratories formally completed a strategic integration at BioMetas’ Shanghai headquarters. The signing ceremony included leadership from both organizations as well as representatives from key shareholders, including CFS Capital, Huagai Capital, Qiming Venture Partners, ACM Capital, and the AstraZeneca CICC Fund.
BioMetas has grown rapidly over the past four years as a globally oriented preclinical CRO, with approximately 85 percent of its revenue generated from international clients. The company has developed core capabilities across early research, including protein science, in vitro and in vivo efficacy evaluation, and DMPK, with particular strength in oncology and autoimmune disease programs.
ZSHK Laboratories brings a complementary set of capabilities centered on GLP toxicology services. The company operates internationally certified GLP facilities in Suzhou and Shenzhen and maintains dedicated animal research infrastructure, including non human primate and canine models. Its services span pharmacokinetics, toxicology, and safety evaluation, with a client base primarily concentrated in the domestic Chinese market.
Following the integration, the combined platform is designed to provide a continuous, end to end preclinical development pathway. The service model spans early research, including target validation, molecular screening, and efficacy studies; translational work, including DMPK and dose exploration; and regulatory support, including GLP safety evaluation, toxicology, and safety pharmacology. By consolidating these capabilities within a single platform, the integrated organization aims to reduce handoff between service providers, improve data consistency, and accelerate timelines toward IND.
The integration also strengthens access to experimental animal resources and expands model coverage across multiple species and disease areas, supporting more complex mechanism studies and advanced preclinical programs.
From a strategic standpoint, the companies have indicated a focus on building a broader service plus capital ecosystem, combining scientific capability, operational scale, and capital market alignment to enhance global competitiveness. The transaction reflects a broader trend within the CRO industry toward platform integration, moving beyond cost driven specialization toward more comprehensive, value oriented service models.
For early stage drug development companies, the implication is clear: an integrated preclinical pathway reduces friction, accelerates timelines, and creates a more coherent progression from discovery through IND enabling studies. With this integration, BioMetas strengthens its ability to deliver fast, cost-efficient, high-quality services within a comprehensive platform, positioning itself as a valuable partner for both domestic Chinese innovation and global programs. This combination of speed, efficiency, and execution quality highlights the growing role of leading platforms like BioMetas in moving China further into the forefront of the global early stage drug development landscape.
Next Phase Newsletter 
Leave a comment